SCHEMBL4262602

SCHEMBL4262602

CCOC(=O)CCc1sc(N)cc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
PTPN1 P18031 1/20 0.48
CYP4F2 P78329 3/20 0.48
CYP4A11 Q02928 3/20 0.48
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 5/20 0.45
HPGD P15428 4/20 0.45
HSD17B10 Q99714 3/20 0.45
RAB9A P51151 3/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ALOX15 P16050 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 1/20 0.43
GRM6 O15303 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6050760 0.76 CYP4F2 (0.50) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL4265764 0.76 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL4266618 0.75 CYP4F2 (0.56) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
Hydrochloric Acid SCHEMBL27782843 0.74 CYP4F2 (0.54) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL28581664 0.74 CYP4F2 (0.61) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL6282888 0.74 CYP4F2 (0.69) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
Succinic Acid Diethyl Ester SCHEMBL27940678 0.72 SMN1; SMN2 (0.62) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2
SCHEMBL3496255 0.72 ALDH1A1 (0.54) ALDH1A1PTPN1SMN1; SMN2MAPTHPGD
SCHEMBL2428470 0.71 CYP4F2 (0.57) ALDH1A1PTPN1CYP4F2CYP4A11MAPT
SCHEMBL15822278 0.71 ALOX5 (0.51) ALDH1A1PTPN1CYP4F2CYP4A11SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
EP-1845081-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048258-A1 Amide Compound DLAT, DGAT1, DGAT2 ALDH1A1 435/4885PTPN1 3426/4885CYP4F2 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.